December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cogent Biosciences, Inc. - Common Stock (NQ:COGT)

34.94 +1.11 (+3.27%)
Streaming Delayed Price Updated: 12:42 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cogent Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Top movers in Monday's session ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Cogent Biosciences Stock Trading Higher On Monday? ↗
Cogent Biosciences' SUMMIT trial shows bezuclastinib improves symptoms and quality of life in systemic mastocytosis, with favorable safety data. 
Via Benzinga
News headline image
Gold Jumps Over 2%; Dole Shares Gain After Q3 Results ↗
 
Via Benzinga
News headline image
Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise ↗
The company is working to improve outcomes for patients with gastrointestinal stromal tumors, or GIST. 
Via Investor's Business Daily
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial ↗
Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial. 
Via Benzinga
News headline image
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
S&P 500 Surges 1%; Tyson Foods Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Monday's pre-market session: top gainers and losers ↗
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results
Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from... 
Via MarketMinute
Topics Economy Supply Chain
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags ↗
According to the technical analysis of over 4,400 firms with a market cap exceeding $100 million, three firms are in the overbought zone. 
Via Benzinga
News headline image
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges ↗
Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential. 
Via Stocktwits
News headline image
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst ↗
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025. 
Via Benzinga
News headline image
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' ↗
U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed. 
Via Benzinga
Topics Artificial Intelligence Government
News headline image
Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear & Greed Index Remains In 'Extreme Greed' Zone ↗
 
Via Benzinga
Topics Government Stocks
News headline image
Dow Dips 1%; Mustang Bio Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Is Cogent Biosciences Stock Trading Higher On Monday? ↗
Cogent reported positive SUMMIT trial data for bezuclastinib in NonAdvSM and plans to file for FDA approval by late 2025. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q2 2024 ↗
COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 ↗
COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.